COVID-19 Antiviral Pill From Roche, Atea Fails to Help Patients With Mild or Moderate Symptoms

COVID-19 Antiviral Pill From Roche, Atea Fails to Help Patients With Mild or Moderate Symptoms
The logo of Swiss pharmaceutical giant Roche is seen in Basel in a file photograph. Sebastien Bozon/AFP via Getty Images
Zachary Stieber
By Zachary Stieber, Senior Reporter
Updated:

A pill developed by two drugmakers failed to help COVID-19 patients with mild or moderate symptoms, one of the companies announced Tuesday.

Atea Pharmaceuticals and Roche tested their experimental treatment in a Phase 2 trial in outpatient settings, or non-hospitalized patients.

Zachary Stieber
Zachary Stieber
Senior Reporter
Zachary Stieber is a senior reporter for The Epoch Times based in Maryland. He covers U.S. and world news. Contact Zachary at [email protected]
twitter
truth
Related Topics